45 Results for "

pRb

" in MedChemExpress (MCE) Product Catalog:
Products (45)

45 Results for "pRb" in MCE Product Catalog:

6
6 Publications Verification
Cat. No.: HY-15166
CAS No.: 937270-47-8
Purity:  99.70%
Synonyms: (E/Z)-TG02; (E/Z)-SB1317
Target:  

CDK JAK FLT3

Research Areas:  

Cancer

(E/Z)-Zotiraciclib ((E/Z)-TG02) is a potent inhibitor of CDK2, JAK2 and FLT3 with IC50s of 13, 73 and 56 nM, respectively. (E/Z)-Zotiraciclib effectively inhibits the proliferation of cancer cells, it can be used for the research of cancer .
6
6 Publications Verification
Cat. No.: HY-15166A
CAS No.: 1321626-25-8
Purity:  99.90%
Synonyms: (E/Z)-TG02 hydrochloride; (E/Z)-SB1317 hydrochloride
Target:  

CDK JAK FLT3

Research Areas:  

Cancer

(E/Z)-Zotiraciclib ((E/Z)-TG02) is an orally active inhibitor of CDK2, JAK2 and FLT3 with IC50s of 13, 73 and 56 nM, respectively. (E/Z)-Zotiraciclib effectively inhibits the proliferation of cancer cells, it can be used for the research of cancer .
1
1 Cited Publications
Cat. No.: HY-158106
CAS No.: 3047321-53-6
Purity:  99.60%
Target:  

CDK

Research Areas:  

Cancer

AZD8421 is a selective CDK2 inhibitor (IC50 = 9 nM) as well as achieving CDK family selectivity in cells versus key off-targets (CDK1, CDK4/6, CDK9), AZD8421 had no significant kinase inhibition outside the CDK family. AZD8421 inhibits cancer cell proliferation by inhibiting pRB phosphorylation, inducing cell cycle arrest in G1/S phase and senescence. AZD8421 can be studied in research for breast cancer and ovarian cancer .
1
1 Cited Publications
Cat. No.: HY-162318
CAS No.: 2946670-96-6
Target:  

Molecular Glues c-Myc

Research Areas:  

Cancer

MYC degrader 1 (compound A80.2HCl) is an orally available MYC molecular glues degrader with anti-tumor activity. MYC degrader 1 restores pRB1 protein activity and re-establishes sensitivity of MYC overexpressing cancer cells to CDK4/6 inhibitors .
1
1 Cited Publications
Cat. No.: HY-112158
CAS No.: 1147-56-4
Purity:  99.86%
Synonyms: ERGi-USU
Target:  

RIO Kinase

Research Areas:  

Cancer

NSC139021 (ERGi-USU) is a RIOK2 inhibitor with anticancer activity. RIOK2 can highly selectively inhibit the growth of ERG-positive cancer cells with IC50s of 30-400 nM against cell lines. RIOK2 also causes cell cycle arrest and apoptosis in glioblastoma via induction of Skp2 and Skp2-p27/p21-Cyclin E/CDK2-pRb signaling .
1
1 Cited Publications
Cat. No.: HY-162318A
Target:  

Molecular Glues c-Myc

Research Areas:  

Cancer

MYC degrader 1 TFA (compound A80.2HCl) is an orally available MYC molecular glues degrader with anti-tumor activity. MYC degrader 1 TFA restores pRB1 protein activity and re-establishes sensitivity of MYC overexpressing cancer cells to CDK4/6 inhibitors .
Cat. No.: HY-129180
CAS No.: 2229974-73-4
Purity:  98.62%
Target:  

PROTACs CDK

Research Areas:  

Cancer

XY028-133 (example 14) is a PROTAC-based CDK4/6 degrader with anti-tumor activity, which consists of ligands for von Hippel-Lindau and CDK .
Cat. No.: HY-122620
CAS No.: 2114365-78-3
Purity:  98.33%
Synonyms: Hetrombopag (tautomerism); SHR-8735 (tautomerism)
Rafutrombopag (tautomerism) (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR‐expressing cells, including 32D‐ MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .
Cat. No.: HY-136726
CAS No.: 359886-84-3
Purity:  98.12%
Synonyms: CINK4
Target:  

CDK

Research Areas:  

Cancer

GP-82996 (CINK4) is a pharmacological inhibitor of CDK4/6. GP-82996 has IC50s of 1.5, 5.6 and 25 μM for CDK4/cyclin D1, CDK6/cyclin D1 and Cdk5/p35, respectively. GP-82996 induces the apoptosis of cancer cells U2OS. GP-82996 can be used in the research of cancer .
Cat. No.: HY-145589
CAS No.: 2600513-51-5
Synonyms: Hetrombopag; SHR-8735
Rafutrombopag (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR-expressing cells, including 32D-MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .
Cat. No.: HY-201330
CAS No.: 2531743-46-9
Synonyms: RGT-419B
Target:  

CDK

Research Areas:  

Cancer

GDC-4198 (RGT-419B) is an orally active CDK4/2 inhibitor with desired degrees of selectivity against kinases such as CDK6, CDK9 and GSK3β. GDC-4198 inhibits the activity of cyclin-CDK complexes, blocks phosphorylation of the retinoblastoma protein (pRb), arresting the cell cycle transition from G1 to S phase. GDC-4198 is promising for research of cancers, such as breast cancer (especially hormone receptor-positive, HER2-negative type), lung cancer, and colorectal cancer .
Cat. No.: HY-RS11051
Research Areas:  

Others

PRB1 Human Pre-designed siRNA Set A contains three designed siRNAs for PRB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-RS11052
Research Areas:  

Others

PRB2 Human Pre-designed siRNA Set A contains three designed siRNAs for PRB2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-RS11053
Research Areas:  

Others

PRB3 Human Pre-designed siRNA Set A contains three designed siRNAs for PRB3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-RS11054
Research Areas:  

Others

PRB4 Human Pre-designed siRNA Set A contains three designed siRNAs for PRB4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-RS10397
Research Areas:  

Others

Pgr Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pgr gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-147220
CAS No.: 4089-36-5
Synonyms: Dex-Ox
Target:  

Progesterone Receptor

Research Areas:  

Endocrinology

Dexamethasone oxetanone (Dex-Ox), a derivative of the glucocorticoid-selective steroid Dexamethasone (Dex), is an antiglucocorticoid. Dexamethasone oxetanone is an antiprogestin with significant agonist activity with progesterone receptor (PR) A and B isoforms .
Cat. No.: HY-RS11713
Research Areas:  

Others

RB1 Human Pre-designed siRNA Set A contains three designed siRNAs for RB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-16290
CAS No.: 211254-73-8
Synonyms: ZK 230211; BAY86 5044
Target:  

Progesterone Receptor

Research Areas:  

Endocrinology

Lonaprisan (ZK 230211; BAY86 5044) is an antagonist for progesterone receptor, with IC50 of 3.6 pM and 2.5 pM for PR-A and PR-B, respectively. Lonaprisan exhibits antiprogestagenic activity in rabbits, interrupts early pregnancy in rats, and exhibits antitumor efficacy against DMBA (HY-W011845)-induced mammary tumor. Lonaprisan reveals antiglucocorticoid and antiandrogenic effect .
Cat. No.: HY-173007
CAS No.: 3050831-84-7
ALK/PI3K/AKT-IN-1 (Compound 45) inhibits the proliferation of cancer cell A549, H1975 and PC9 with an IC50 of 0.44, 0.83 and 1.51 μM. ALK/PI3K/AKT-IN-1 increases the expression of p21 and p27, inhibits the activity of CDK2 and p-Rb, arrests the cell cycle at G1 phase. ALK/PI3K/AKT-IN-1 inhibits the ALK/PI3K/AKT signaling pathway, promotes the depolarization of mitochondrial membrane potential, and inducing apoptosis in A549 cell. ALK/PI3K/AKT-IN-1 inhibits the formation and growth of A549 cell spheroids .